[ TRANSACTION RECORD ]

JPMorgan Chase & Co. Investment in Horizon Therapeutics — 2023

VERIFIED VECTOR ID: 002132 · tx-228
M SOURCE NODE — FUNDER
JPMorgan Chase & Co.
Finance United States
$27,800,000,000
EQUITY
06/10/2023
Q DESTINATION NODE — RECIPIENT
Horizon Therapeutics
Company Ireland
Amount (USD)
$27.8B
Flow Type
EQUITY
Transaction Date
06/10/2023
Primary Source
View Filing ↗
Funder Profile [ M ]
Entity JPMorgan Chase & Co.
AUM 3900000
HQ Location United States
Sector Finance
Recipient Profile [ Q ]
Entity Horizon Therapeutics
Entity Type Company
Jurisdiction Ireland
Intelligence Note

Amgen finalized the 27.8 billion dollar acquisition of Horizon Therapeutics to strengthen its portfolio of medicines for rare inflammatory and orphan diseases. This transaction provides Amgen with high-growth therapies such as Tepezza for thyroid eye disease. The deal represents a significant institutional investment in the specialized healthcare and biotech market.

Σ
Primary Forensic Source https://www.amgen.com/newsroom/press-releases/2023/10/amgen-completes-acquisition-of-horizon-therapeutics-plc/
✓ SOURCE LINKED